Search

Displaying results 2511 - 2520 of 4301 in total
  1. Drug

    CYT006-AngQb

    go.drugbank.com/drugs/DB05739
    Investigational

    It is a unique treatment modality that aims to address the issue of patient compliance by offering convenient dosing schedules due to the long-lasting effect induced by vaccination.

  2. Drug

    Neisseria meningitidis group w-135 capsular polysaccharide diphtheria toxoid conjugate antigen

    go.drugbank.com/drugs/DB10801
    ApprovedInvestigational

    Neisseria meningitidis group w-135 capsular polysaccharide diphtheria toxoid conjugate antigen is an active intramuscular immunization for the prophylaxis of invasive meningococcal disease caused by *Neisseria

  3. Drug

    Risankizumab

    go.drugbank.com/drugs/DB14762
    ApprovedInvestigational

    [L39885] It gained its first global approval in Japan in March 2019, followed by approval in Canada, the US, and Europe in April 2019.

  4. Drug

    Asenapine

    go.drugbank.com/drugs/DB06216
    ApprovedInvestigational

    Developed by Schering-Plough after its merger with Organon International, asenapine is a sublingually administered, atypical antipsychotic for treatment of schizophrenia and acute mania associated with

  5. Drug

    Sulpiride

    go.drugbank.com/drugs/DB00391
    ApprovedWithdrawn

    [A229683] Sulpiride is not approved by the FDA, Health Canada, or the EMA; though it is approved in individual European countries.[L24679]

  6. Drug

    Trichloroacetate

    go.drugbank.com/drugs/DB11152
    ApprovedInvestigational

    Trichloroacetate, or trichloroacetic acid, is a strong acid prepared by the reaction of chlorine with acetic acid in the presence of a suitable catalyst.

  7. Drug

    Formaldehyde

    go.drugbank.com/drugs/DB03843
    ApprovedVet approved

    A highly reactive aldehyde gas formed by oxidation or incomplete combustion of hydrocarbons.

  8. Drug

    R673

    go.drugbank.com/drugs/DB05466
    Experimental

    The phase II program for treatment of depression and anxiety is ongoing in the US and EU.It is not clear how tachykinin antagonists exert their effect, but SP levels have been commonly linked to the functioning

  9. Drug

    Dexamethasone acetate

    go.drugbank.com/drugs/DB14649
    ApprovedInvestigationalVet approved

    [A188724] Dexamethasone acetate has largely been replaced by [dexamethasone] phosphate and continues to be administered for a large variety of inflammatory conditions. … In a June 16 2020 press release highlighting early results of a clinical trial, Randomized Evaluation of COVID-19 Therapy (RECOVERY), it was reported that dexamethasone reduced COVID-19 deaths by approximately

  10. Drug

    Gadopiclenol

    go.drugbank.com/drugs/DB17084
    ApprovedInvestigational

    [A254002,A254017] In September 2022, the use of gadopiclenol was approved by the FDA. … [L43817] In 2006, the use of GBCAs was associated with the development of nephrogenic systemic fibrosis (NSF), a rare disorder characterized by the thickening and hardening of skin and subcutaneous tissues